Furosemide controlled release - scPharmaceuticals

Drug Profile

Furosemide controlled release - scPharmaceuticals

Alternative Names: Furoscix; Furosemide micropump patch - scPharmaceuticals/Sensile Medical; sc2Wear furosemide Infusor - scPharmaceuticals/Sensile Medical; SCP-101

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator scPharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Small molecules; Sulfanilamides
  • Mechanism of Action Loop diuretics; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Oedema

Most Recent Events

  • 13 Jun 2018 scPharmaceuticals receives complete response letter from the FDA for furosemide controlled release in Oedema (In patients with heart failure)
  • 07 May 2018 scPharmaceuticals has patent protection for furosemide controlled release in USA
  • 07 May 2018 scPharmaceuticals intends to launch furosemide controlled release for Oedema (with chronic heart failure) in USA in the fourth quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top